TVTX · Categories · Coverage
TVTX - Analyst coverage initiated
Travere Therapeutics Inc. (TVTX) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for TVTX
- Cantor Fitzgerald initiated coverage on Travere TherapeuticsCantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight
- Scotiabank initiated coverage on Travere TherapeuticsScotiabank initiated coverage of Travere Therapeutics with a rating of Sector Outperform
- Citigroup initiated coverage on Travere Therapeutics with a new price targetCitigroup initiated coverage of Travere Therapeutics with a rating of Neutral and set a new price target of $7.00
- JP Morgan initiated coverage on Travere Therapeutics with a new price targetJP Morgan initiated coverage of Travere Therapeutics with a rating of Overweight and set a new price target of $26.00
- TD Cowen initiated coverage on Travere Therapeutics with a new price targetTD Cowen initiated coverage of Travere Therapeutics with a rating of Outperform and set a new price target of $30.00
- Guggenheim initiated coverage on Travere Therapeutics with a new price targetGuggenheim initiated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $37.00
- Stifel initiated coverage on Travere Therapeutics with a new price targetStifel initiated coverage of Travere Therapeutics with a rating of Hold and set a new price target of $22.00
- Wells Fargo initiated coverage on Travere Therapeutics with a new price targetWells Fargo initiated coverage of Travere Therapeutics with a rating of Overweight and set a new price target of $28.00
- Bryan Garnier initiated coverage on Travere Therapeutics with a new price targetBryan Garnier initiated coverage of Travere Therapeutics with a rating of Sell and set a new price target of $17.00
- Piper Sandler initiated coverage on Travere Therapeutics with a new price targetPiper Sandler initiated coverage of Travere Therapeutics with a rating of Overweight and set a new price target of $42.00
- HC Wainwright & Co. initiated coverage on Travere Therapeutics with a new price targetHC Wainwright & Co. initiated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $45.00